Showing results (21-30 of 84) with videos related to
Sort By:
Pageof 9
Cancer|June 20, 2007
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trialsEmilio Bria, Michele Milella, Alain Gelibter, et al.Cancers|December 24, 2021
Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective StudyMarta Tenuta, Alain Gelibter, Carla Pandozzi, et al.International Journal of Clinical and Experimental Pathology|August 15, 2025
Evaluation of immune microenvironment in non-small cell lung carcinoma after neoadjuvant immunotherapy: a case reportMartina Leopizzi, Angelina Pernazza, Emma Rullo, et al.Frontiers in Oncology|May 10, 2021
Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical PracticeMichela Roberto, Andrea Botticelli, Martina Panebianco, et al.Oncology|February 28, 2009
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancersMaria S Pino, Michele Milella, Alain Gelibter, et al.Clinical and Experimental Medicine|April 10, 2024
Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohortFulvia Ceccarelli, Francesco Natalucci, Licia Picciariello, et al.Current Drug Targets|March 31, 2012
Molecular and genetic bases of pancreatic cancerVanja Vaccaro, Alain Gelibter, Emilio Bria, et al.International Journal of Molecular Sciences|April 13, 2024
Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint InhibitorsValentina Magri, Gianluigi De Renzi, Luca Marino, et al.Cancer Chemotherapy and Pharmacology|December 12, 2007
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluationAlessandra Fabi, Giulio Metro, Paola Papaldo, et al.Cancer Immunology Research|April 28, 2018
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin PathwayIlaria Grazia Zizzari, Chiara Napoletano, Andrea Botticelli, et al.Pageof 9